204 related articles for article (PubMed ID: 19295017)
21. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma.
Isaka K; Nishi H; Nakai H; Nakada T; Feng Li Y; Ebihara Y; Takayama M
Cancer; 2003 Jan; 97(1):79-89. PubMed ID: 12491508
[TBL] [Abstract][Full Text] [Related]
22. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
Laas E; Ballester M; Cortez A; Gonin J; Daraï E; Graesslin O
Gynecol Oncol; 2014 May; 133(2):205-10. PubMed ID: 24556060
[TBL] [Abstract][Full Text] [Related]
23. Expression of cold-inducible RNA-binding protein in the normal endometrium, endometrial hyperplasia, and endometrial carcinoma.
Hamid AA; Mandai M; Fujita J; Nanbu K; Kariya M; Kusakari T; Fukuhara K; Fujii S
Int J Gynecol Pathol; 2003 Jul; 22(3):240-7. PubMed ID: 12819390
[TBL] [Abstract][Full Text] [Related]
24. Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival.
Giuffrè G; Arena F; Scarfì R; Simone A; Todaro P; Tuccari G
Oncol Rep; 2006 Aug; 16(2):257-63. PubMed ID: 16820900
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma.
Weigel MT; Krämer J; Schem C; Wenners A; Alkatout I; Jonat W; Maass N; Mundhenke C
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):74-8. PubMed ID: 22056701
[TBL] [Abstract][Full Text] [Related]
26. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression.
Mora LB; Diaz JI; Cantor AB; Nicosia SV
Ann Clin Lab Sci; 1999; 29(4):308-15. PubMed ID: 10528831
[TBL] [Abstract][Full Text] [Related]
27. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
Ma XX; Zhang SL; Gao S; Lu JM; Dong F
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
[TBL] [Abstract][Full Text] [Related]
28. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
29. Loss of Smad4 protein expression occurs infrequently in endometrial carcinomas.
Liu FS; Chen JT; Hsieh YT; Ho ES; Hung MJ; Lu CH; Chiou LC
Int J Gynecol Pathol; 2003 Oct; 22(4):347-52. PubMed ID: 14501814
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer.
Pilka R; Norata GD; Domanski H; Andersson C; Hansson S; Eriksson P; Casslén B
Gynecol Oncol; 2004 Sep; 94(3):661-70. PubMed ID: 15350356
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women.
Konishi I; Koshiyama M; Mandai M; Kuroda H; Yamamoto S; Nanbu K; Komatsu T; Matsushita K; Rao CV; Mori T
Gynecol Oncol; 1997 May; 65(2):273-80. PubMed ID: 9159337
[TBL] [Abstract][Full Text] [Related]
32. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
34. [Proliferative activity of normal endometrial cells, endometrial hyperplasia cells and endometrial cancer cells using the monoclonal antibody to PCNA].
Hareyama H
Hokkaido Igaku Zasshi; 1994 Nov; 69(6):1427-1. PubMed ID: 7705752
[TBL] [Abstract][Full Text] [Related]
35. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
36. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
37. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.
Uchikawa J; Shiozawa T; Shih HC; Miyamoto T; Feng YZ; Kashima H; Oka K; Konishi I
Cancer; 2003 Nov; 98(10):2207-13. PubMed ID: 14601091
[TBL] [Abstract][Full Text] [Related]
38. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium.
Elhafey AS; Papadimitriou JC; El-Hakim MS; El-Said AI; Ghannam BB; Silverberg SG
Arch Pathol Lab Med; 2001 Jul; 125(7):872-9. PubMed ID: 11419970
[TBL] [Abstract][Full Text] [Related]
39. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
[TBL] [Abstract][Full Text] [Related]
40. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
